| ||
| Diabetes Drug Actos (pioglitazone) Review Initiated To Determine Possible ... Medical News Today Actos (pioglitazone), a diabetes medication is being reviewed by the FDA (Food and Drug Administration) after it received a long-term observational study which evaluated the risk of bladder cancer. The preliminary results of the 10-year observational ... See all stories on this topic » | ||
| Pazopanib Shows Promising Results For Advanced Thyroid Cancer Patients Medical News Today A Phase II clinical trial with Pazopanib for the treatment of advanced differentiated thyroid cancer which stops tumor blood vessel growth had promising results. 49% of patients responded positively to Pazopanib therapy, their tumors shrank - the ... See all stories on this topic » | ||
| Roche's Avastin Fails to Help Early-Stage Colon Cancer Patients in Study Bloomberg By Carey Sargent - Sat Sep 18 16:01:14 GMT 2010 Roche Holding AG's Avastin tumor medicine failed to meet the main goal of a late-stage study in early colon cancer. A combination of Avastin and chemotherapy given immediately after surgery didn't extend ... See all stories on this topic » | ||
| Absent Father Might Mean Earlier Puberty for Higher-Income Girls BusinessWeek By Kathleen Doheny FRIDAY, Sept. 17 (HealthDay News) -- Girls growing up in higher-income homes without a biological father are likely to reach puberty earlier than others, new research finds. "In higher-income families, father absence predicted ... See all stories on this topic » | ||
| More Maternal Education Saves Children's Lives BusinessWeek FRIDAY, Sept. 17 (HealthDay News) -- Increasing levels of education among women worldwide helped save the lives of millions of children a year, a new study shows. Between 1970 and 2009, the average number of years of education among women aged 25 and ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment